SymbioCellTech's Unattributed - III Round

SymbioCellTech raised a round of funding on August 28, 2017.

SymbioCellTech is a biotechnology start-up that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juve…

Articles about SymbioCellTech's Unattributed - III Round: